Abstract: The disclosure provides, inter alia, compositions including cell-nanoparticle constructs and drug loaded nanoparticles, and methods for their use in the treatment of cancer. Also provided are unmodified cisplatin molecules encapsulated by silica nanoparticles, and their use in the treatment of cancer.

Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.

Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.

Abstract: Disclosed herein, inter alia, are methods for detecting cancer using nanoparticles.

Abstract: The disclosure provides, inter alia, neural stem cells comprising exogenous nucleotides, vesicles comprising exogenous nucleotides, and methods for treating diseases and disorders, such as cancer, neurodegenerative diseases, inflammatory diseases, and viral diseases, using the neural stem cells, vesicles, and pharmaceutical compositions comprising them.

Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.

Abstract: A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition. a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

Abstract: A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

Abstract: Disclosed herein, inter alia, are compositions and methods of using the same for treating cancer.

Abstract: Disclosed herein, inter alia, are methods for detecting cancer using nanoparticles.

Abstract: A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

Abstract: A subpopulation of cancer stem cells expressing elevated levels of uPAR have been identified among a population of cancer cells. Methods are provided for treating proliferative disorders such as cancer by administering one or more uPAR inhibitors. Methods are likewise provided for predicting the likelihood of recurrence of a cancer, preventing recurrence of a cancer, and identifying the likelihood of a cancer to respond to a particular cancer therapy.

Abstract: A subpopulation of cancer stem cells expressing elevated levels of uPAR have been identified among a population of cancer cells. Methods are provided for treating proliferative disorders such as cancer by administering one or more uPAR inhibitors. Methods are likewise provided for predicting the likelihood of recurrence of a cancer, preventing recurrence of a cancer, and identifying the likelihood of a cancer to respond to a particular cancer therapy.

Abstract: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.

Abstract: One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and distribute themselves throughout the tumor in juxtaposition to widely expanding and aggressively advancing tumor cells, while continuing to express a foreign reporter gene. Furthermore, drawn somewhat by the degenerative environment created just beyond the infiltrating tumor edge, the neural progenitor cells migrate slightly beyond and surround the invading tumor border. When implanted at a distant sight from the tumor bed (e.g., into normal tissue, into the contralateral hemisphere, into the lateral ventricles) the donor neural progenitor/stem cells will migrate through normal tissue and specifically target the tumor cells.

Abstract: The present invention relates to the field of cellular and molecular therapy with modified (genetically or growth factor engineered) and unmodified stem cells (SCs). More particularly, the invention relates to a method of systemic treatment of central nervous system (CNS) and other tumors in both intracranial/intraspinal and extracranial/extraspinal sites, using neural stem cells (NSCs), a prototype for solid organ, non-hematopoietic stem cells.

Abstract: One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and distribute themselves throughout the tumor in juxtaposition to widely expanding and aggressively advancing tumor cells, while continuing to express a foreign reporter gene. Furthermore, drawn somewhat by the degenerative environment created just beyond the infiltrating tumor edge, the neural progenitor cells migrate slightly beyond and surround the invading tumor border. When implanted at a distant sight from the tumor bed (e.g., into normal tissue, into the contralateral hemisphere, into the lateral ventricles) the donor neural progenitor/stem cells will migrate through normal tissue and specifically target the tumor cells.